Alkermes plc Announces Results from Phase 2 Study of ALKS 37 for Treatment of Opioid-Induced Constipation

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced topline results from a phase 2b dose-ranging clinical study of ALKS 37 in the treatment of opioid-induced constipation. The multice…
Read the full story: BioSpace.com Featured News